Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

2021 ◽  
Author(s):  
Caron A Jacobson ◽  
Julio C Chavez ◽  
Alison R Sehgal ◽  
Basem M William ◽  
Javier Munoz ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Phase 2 ◽  
Multicentre Phase ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial

scholarly journals An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

2018 ◽  
Vol 184 (2) ◽  
pp. 215-222 ◽  
Author(s):  
David J. Andorsky ◽  
Kathryn S. Kolibaba ◽  
Sarit Assouline ◽  
Andres Forero‐Torres ◽  
Vicky Jones ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
Phase 2 ◽  
Open Label ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial ◽  
Mantle Cell ◽  
Open Label Phase

scholarly journals Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial

2018 ◽  
Vol 5 (4) ◽  
pp. e170-e180 ◽  
Author(s):  
Jennifer R Brown ◽  
Mehdi Hamadani ◽  
John Hayslip ◽  
Ann Janssens ◽  
Nina Wagner-Johnston ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Hodgkin Lymphoma ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial ◽  
Open Label Phase

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma

Cancer ◽  
2008 ◽  
Vol 112 (4) ◽  
pp. 856-862 ◽  
Author(s):  
Pier Luigi Zinzani ◽  
Monica Tani ◽  
Stefano Fanti ◽  
Vittorio Stefoni ◽  
Gerardo Musuraca ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Phase 2 ◽  
Ibritumomab Tiuxetan ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial ◽  
Yttrium 90

DYNAMO: A phase 2 trial of the PI3K-δ,γ inhibitor IPI-145 in patients with refractory indolent non-Hodgkin lymphoma.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS8619-TPS8619
Author(s):  
Nina Wagner-Johnston ◽  
Donald K Strickland ◽  
David Donald Wright ◽  
Scott A. Tetreault ◽  
Scott D. Lunin ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Phase 2 ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial

scholarly journals Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma

Cancer ◽  
2012 ◽  
Vol 119 (2) ◽  
pp. 371-379 ◽  
Author(s):  
Daruka Mahadevan ◽  
Joseph M. Unger ◽  
Catherine M. Spier ◽  
Daniel O. Persky ◽  
Fay Young ◽  
...  
Keyword(s):  
T Cell ◽  
Hodgkin Lymphoma ◽  
Phase 2 ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial

Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 7059-7059 ◽  
Author(s):  
Paul M. Barr ◽  
Gene Brian Saylors ◽  
Stephen Edward Forbes Spurgeon ◽  
Bruce D. Cheson ◽  
Daniel Reif Greenwald ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Hodgkin Lymphoma ◽  
Lymphocytic Leukemia ◽  
Phase 2 ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial ◽  
Syk Inhibitor
Sign in / Sign up

Export Citation Format

Share Document